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Cardiovascular disease (CVD) constitutes one of the major causes of deaths and disabilities, globally claiming 17.3
million lives a year. Incidence of CVD is expected to rise to 25 million by 2030, and Saudi Arabia, already witnessing a
rapid rise in CVDs, is no exception. Statins are the drugs of choice in established CVDs. In the recent past, evidence
was increasingly suggesting benefits in primary prevention. But over the last decade Saudi Arabia has a witnessed
significant rise in CVD-related deaths. Smoking, high-fat, low-fiber dietary intake, lack of exercise, sedentary life, high
blood cholesterol and glucose levels were reported as frequent CVD-risk factors among Saudis, who may therefore be
considered for primary prevention with statin. The prevalence of dyslipidemia, in particular, indicates that treatment
should be directed at reducing the disorder with lipid-modifying agents and therapeutic lifestyle changes.
The recent American College of Cardiology (ACC)/American Heart Association (AHA) guidelines has reported
lowering the low-density lipoprotein cholesterol (LDL-C) target levels, prescribed by the 2011 European Society of
Cardiology (ESC)/the European Atherosclerosis Society (EAS). The new ACC/AHA guidelines have overemphasized
the use of statin while ignoring lipid targets, and have recommended primary prevention with moderate-intensity
statin to individuals with diabetes aged 40–75 years and with LDL-C 70–189 mg/dL. Treatment with statin was based
on estimated 10-year atherosclerotic-CVD (ASCVD) risk in individuals aged 40–75 years with LDL-C 70 to 189 mg/dL
and without clinical ASCVD or diabetes. Adoption of the recent ACC/AHA guidelines will lead to inclusion of a
large population for primary prevention with statins, and would cause over treatment to some who actually would
not need statin therapy but instead should have been recommended lifestyle modifications. Furthermore, adoption
of this guideline may potentially increase the incidences of statin intolerance and side-effects. On the other hand,
the most widely used lipid management guideline, the 2011 ESC/EAC guidelines, targets lipid levels at different
stages of disease activity before recommending statins. Hence, the 2011 ESC/EAC still offers a holistic and pragmatic
approach to treating lipid abnormalities in CVD. Therefore, it is the 2011 ESC/EAC guidelines, and not the recent
ACC/AHA guidelines, that should be adopted to draw guidance on primary prevention of CVD in Saudi Arabia.
 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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Cardiovascular disease (CVD) is one of themost prevalent diseases in healthy men
and women and globally a major cause of death
and disability. According to a report, CVD includ-
ing heart attacks and strokes claim the lives of 17.3
million people every year. It has been estimated
that this figure is likely to reach 25 million people
in 2030 if no effective interventions are available
[1]. A study from the Middle East reports that
the rate of increase in CVD-associated mortalities
is one of the highest in the world [2]. In Saudi
Arabia, CVD accounts for over 22% of deaths each
year, and other estimates showed over 42% of all
deaths are attributed to CVD in Saudi Arabia
[3,4]. Another study from Saudi Arabia reports a
similar prevalence pattern of diseases to the
West, with cardiac and respiratory disorders
reported as the most frequent, and diabetes and
ischemic heart disease as the main causes forhospitalization [5]. In oil-rich Middle Eastern
countries there have been drastic changes in life-
styles accompanied by several CVD-risk factors
which include smoking, eating high fat (especially
red meat) and low-fiber diets, increased waist-
to-hip ratio, and increased blood cholesterol and
sugar, among other factors. Most of the young
generation of Saudis have multiple risk factors.
Statins provide proven benefits in the secondary
prevention of CVDs while accumulating reports
suggest statins also provide primary prevention
of CVD [6]. The present review discusses statins
in the primary prevention of CVD in Saudi
Arabia in light of current and past lipid manage-
ment guidelines.Statins and their mechanism of action
Statins, 3-hydroxy-3-methylglutaryl-coenzyme
A (HMG-CoA) reductase inhibitors, are a class of
lipid lowering drugs that have revolutionized
CVD pharmacotherapy. This class of lipid lower-
ing agents competitively inhibit the rate limiting
step in lipid biosynthesis, i.e., conversion of
HMG-CoA to mevalonate, leading to the preven-
tion of cholesterol biosynthesis. Over the past
few years, the medical literature has reported that
statins could reduce vascular inflammation and
the development of atherosclerosis through a
mechanism independent of their lipid lowering
effects, referred to as ‘‘pleiotropic effects’’ (Fig. 1).
The lipid-independent effects of statins are
reported to result from inhibition of isoprenoids
(geranylgeranyl pyrophosphate), the products of
which are important lipid attachments for a host
of intracellular signaling proteins [7] and hence
inhibit the activation of various signaling proteins
which include heme A, nuclear lamins, and small
guanosine triphosphate bound Ras and Ras-like
proteins, which include Rho, Rac and Cdc42, and
the c-subunit of heterotrimeric G-proteins [8].
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Figure 1. Diagrammatic elucidation of mechanisms of statins; HMG-CoA: hydroxyl methyl glutaryl-coenzyme A; PP: pyrophopspahte.
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PRIMARY PREVENTION WITH STATINS IN CARDIOVASCULAR DISEASESThese proteins are reported as critical for control-
ling a host of cellular functions, which include
cellular growth and differentiation, expression of
genes, cytoskeletal assembly, and cell motility in
the transport of proteins and lipids, nuclear
transport, and cellular immunity. Statins were
reported to display anti-inflammatory, antioxidant,
antiplatelet, antiproliferative, and immunosup-
pressive properties [9–11]. Statins cause plaque
stability through combined reduction of lipids,
macrophages, and matrix metalloproteinases,
and prevent endothelial dysfunction by inhibiting
isoprenylation of Rac and Rho, and activation of
the Rho-associated kinases pathway [12,13].Primary prevention with statins in
cardiovascular diseases
The clinical and preclinical literature is replete
with findings that treatment with statins signifi-
cantly reduces occurrence of deaths and disabili-
ties in patients with known clinical manifestation
of CVD [14–16]. Statins, therefore, are widely used
and are the most effective hypolipidemic agents
available to clinicians for the reduction of cardio-
vascular risks and prevention of the worsening
of disease/disability in patients with established
CVD (secondary prevention). Primary prevention
refers to interventions that aim to assess and
manage cardiovascular risk in people who have
not yet developed or clinically manifested CVDwhich may further help to prevent future disease
in asymptomatic individuals with risk factors. In
primary prevention strategy, statin use has
remained a debatable topic in patients at rela-
tively low risk and without the manifestation of
CVD. However, a meta-analysis of a large statin
trial reported over one-fourth relative reduction
in the risk of cardiovascular events in both pri-
mary and secondary prevention with statin, and
also in patients with varying risk factor profiles
[15]. The guidelines on cholesterol treatment rec-
ommends use of statin therapy in primary preven-
tion based on CVD profile and low density
lipoprotein (LDL)-C level of patients [17]. In addi-
tion, the guidelines recommend statin therapy
only in patients with average or below average
risk for diabetes mellitus (with LDL-C levels
<160 mg/dL), and two or more risk factors [14].
In 2009, Brugts et al. [16] reported a meta-analysis
of 10 randomized clinical trials (RCT) that
involved 16,078 and 23,681 men and women,
respectively, with diabetes mellitus, and had a
mean follow-up of 4.1 years. The findings of the
meta-analysis showed that there was a consider-
able lowering of all cause mortality, major
coronary and cerebrovascular events with the
treatment of statin, and that the statin treatment
did not increase the risk of cancer. No significant
differences were observed with respect to the
treatment effects in the study sub-populations.
Hence, it was concluded that in asymptomatic
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ment with statin considerably increased survival
rate, and showed greater reduction in the risk of
major cardiovascular events [16]. However, in
day-to-day clinical practices, statin therapy is
reported as costly for primary prevention in indi-
viduals considered to be at low risk of vascular
disease, despite the fact that generic statins are
available at considerably low costs. It was
suggested that the cost of statin therapy in pri-
mary prevention could be reduced through strict
adherence to statin therapy [18].
In 2011, Taylor et al. [19] reported a meta-analy-
sis for primary prevention with statins. The study
involved 14 randomized control trials conducted
from 1994 to 2006. In this study, all randomized
control trials compared statins with the dummy
or usual care, and consisted of 61 year treatment
and a six-month follow-up period. The findings
of the meta-analysis revealed a significant reduc-
tion in statin side effects, muscle pain, including
cancer. The study also showed reduction in all-
cause mortality and revascularization process with
statin treatment in individuals without manifesta-
tions of CVD. Recently, Taylor et al. [20] reported
another systematic review that included 18 RCTs
with statins. The study compared statin treatment
with a dummy or usual care control with 61 year
and a six-month follow-up period in adults
without restrictions on total, LDL, or high density
lipoprotein (HDL) cholesterol levels, and where
10% or less of study participants had a history of
CVD. However, the study included only 14 clinical
studies that involved study participants with
particular disease conditions such as hypercholes-
terolemia, diabetes, hypertension, and micro-
albuminuria. It was observed that statins reduced
all-cause mortality, relative risk of combined fatal
and non-fatal congestive heart disease (CHD),
stroke, and CVD. There was a reduction of revas-
cularization rates. Total cholesterol and LDL-C
were reported to have been reduced in all the
studies. The authors did not find any deleterious
effects with the use of statins. Further, they were
of the opinion that statins for primary prevention
could be worthwhile and would improve quality
of life in patients [20]. The Cholesterol Treatment
Trialists study that included individual patient
data report indicated that the benefits accrued
with statin use were similar in people at lower (less
than one percent per year) risk of a major cardio-
vascular event. Therefore, the study supported
findings that statins reduced all-cause mortality,
major vascular events and revascularizations in indi-
viduals without clinical manifestation of CVD [20].In 2012, de Vries et al. reported that primary
prevention with statins among diabetic patients
had a significant beneficial effect on event rates
for first-time occurrence of a major cardiovascular
or cerebrovascular event, fatal/non-fatal stroke
and fatal/non-fatal myocardial infarction (MI)
[21]. A review of the literature on the primary pre-
vention of statins reported considerable reduction
in cardiovascular morbidity over the short and
long term, and a general trend towards a reduc-
tion in mortality over the long term. Taken
together, these data provided some of the stron-
gest evidence supporting statin use in primary
prevention in individuals with cardiovascular risk
factors for developing CHD over the next 10 years
[22].
Two meta-analyses [24] published after 2012
unequivocally supported statins for primary pre-
vention. In one of the studies, a 9% decrement
was noted in all-cause mortality and a 25% lower-
ing of major vascular events with every mmol/L
reduction of LDL-C level, even among low-risk
asymptomatic patients [23]. The finding of this
study was supported by another recent systematic
review in which a 14% decrement in all-cause
mortality and a 25% lowering of CVD events were
reported with statin use [20].
In 2013, Minder et al. [24] reported that statins
effectively lowered LDL, very-low-density lipo-
protein, and intermediate-density lipoproteins
cholesterol particles, resulting in clinically
significant lowering of cardiovascular deaths/
disabilities. From these findings, it was concluded
that primary prevention with statins in cardiovas-
cular benefits outweigh its adverse effects [24].
There remains palpable doubt in the mind of clini-
cians over the prescription of statins, as consensus
cannot be built on the distinction of low-risk,
moderate-risk, or high lifetime risk of CVD among
patients. Further, it is not possible to unequivo-
cally establish whether those at low-risk or
moderate-risk have benefited from primary
prevention with statins. It has therefore been
suggested that statin use should either be individ-
ualized for the low-risk group or be based on
clinical judgment in order to reduce undue life-
long statin prescription to apparently healthy
individuals and considerably lower health costs
for individuals [6].Clinical evidence for primary prevention
with statins
Patients have a substantial risk for future
cardiovascular events and premature death if they
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erosclerosis or diabetes. Hypolipidemic therapy is
regarded as the therapy of choice in the preven-
tion of CVD, and use of this therapy has largely
outweighed the risk associated with disease treat-
ment [25,26].
In 1995, Shepherd et al. [27] investigated pri-
mary prevention with pravastatin in a clinical
study that involved 6595 patients with hypercho-
lesterolemia and with a relatively low risk of
CVD. Pravastatin, at a dose of 40 mg, demon-
strated a 32% decrement in the risk of major car-
diovascular events over a follow-up period of
4.9 years. In 1997, Down et al. [28] confirmed the
efficacy and safety of another important statin,
lovastatin, in healthy human subjects (lower-risk
groups). This study showed that lovastatin
reduced the occurrence of major coronary events
by 39%, confirming the benefits of statin treatment
among healthy human subjects [28,29].
In a 2002 clinical study involving 1585 subjects
taking pravastatin, Shepherd and coworkers [30]
reported a higher risk of cancer and other side
effects among these subjects. However, later sev-
eral studies [30–35] demonstrated statins’ positive
association with low risk of coronary and other
CVD-related disorders, no increased risk of
cancer, and provided the critical evidence for sta-
tin use in the primary prevention of diabetes. The
National Institute for Health and Care Excellence
in the United Kingdom proposed a threshold of
CHD risk ofP20% over 10 years for the introduc-
tion of statins for primary prevention in patients
with type 2 diabetes [36]. In 2006, Nakamura
et al. [37] conducted a clinical study that favored
primary prevention with statin therapy. This
study involved 3966 Japanese women with
increased blood cholesterol concentration. Study
participants were randomly allocated in two
groups, which included diet and diet plus prava-
statin (10–20 mg), and followed-up over a period
of 5.3 years. The study results showed that prava-
statin reduced the risk of coronary events by 23%
and without any significant difference in the risk
of cancer or other side-effects between the two
groups.
In 2010, Chan and colleagues [38] reported on
a trial that assessed the intensive lipid lowering
effects of rosuvastatin on the progression of
aortic stenosis in asymptomatic patients with
mild to moderate aortic stenosis. In this trial,
however, a 40 mg dose of rosuvastatin failed
to reduce the rate of progression of aortic
stenosis in patients with mild to moderate aortic
stenosis.In 2008, in a major landmark intervention trial
evaluating rosuvastatin, Hlatky [39] highlighted
the advantages of primary prevention with statins.
The trial was a double-blind, placebo-controlled,
multicenter, randomized trial conducted at more
than thousand sites across 26 countries and was
financially sponsored by pharmaceutical giant
AstraZeneca. It investigated 20 mg daily dose of
rosuvastatin in decreasing the rate of occurrence
of first major cardiovascular events-nonfatal MI,
stroke (non-fatal), unstable angina (requiring hos-
pitalization), arterial revascularization, and mor-
tality from cardiovascular events in comparison
to placebo [39,40]. This trial potentially changed
the spectrum of statin therapy outward to include
even more of the general population. The trial
recruited around 18,000 healthy subjects with no
known CVD or diabetes, LDL-C level less than
130 mg/dL and a high sensitive C-reactive pro-
teins (CRP) of P2 mg/L. Rosuvastatin decreased
cardiovascular events in patients with both
elevated CRP and LDL <130 mg/dL, but otherwise
healthy. In the rosuvastatin group in this trial, a
lower proportion (0.9%) of patients reported major
cardiac events in comparison to the placebo group
(1.8%) indicating large absolute benefits of treat-
ment with statins, enough to justify the associated
risk and costs [39]. The study also revealed a sig-
nificant lowering of cardiovascular events across
population, such as women, black and Hispanic
populations, for which primary prevention data
were limited. The findings of this trial led to a
revision in primary prevention guidelines. A
summary of major and other primary prevention
trials with statins are summarized in Table 1.Primary prevention in men and women aged
P21 years with LDL-C P190 mg/dL
Individuals P21 years of age with primary and
high LDL-C (P190 mg/dL) are placed in the
highly susceptible category to developing
atherosclerotic-CVD (ASCVD) events during their
lifetime due to genetic predisposition. These
individuals have a greater risk of developing
increased LDL-C levels. Therefore, it was recom-
mended that at age 21, individuals having genetic
predisposition to CVD should be prophylactically
treated with statins even if they were not treated
before or had no prior diagnosis. Treatment with
statins was reported to decrease over 20% risk of
ASCVD with every 39 mg/dL decrease in LDL-C.
It was reported that individuals with LDL-C
P190 mg/dL would need even further reduction
in LDL-C levels and hence, such individuals
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Table 1. Summary of major primary prevention trials with statins.
S.
No.
Trials Trial period/
follow up
Drugs N Primary endpoint Secondary
endpoints
Results
1. WOSCOPS Follow up
4.9 year
Pravastatin,
40 mg every
evening
6595 Occurrence of
nonfatal MI or
CHD death as
first event
Nonfatal MI or
CHD death
Pravastatin treatment in
hypercholesterolemic
patients with symptomatic
CHD, lowers LDL-C,
reduces fatal and nonfatal
CVE rates
2. AFCAPS/
TexCAPS
Follow up
5.2 year
Lovastatin
(20–40 mg/d)
6605
(5608
men
and 997
women)
First acute major
coronary event
Fatal or nonfatal
revascularization;
Fatal or nonfatal
MI, UA; CV
mortality; CHD
deaths
First acute major coronary
event reduced by 37%, MI by
40%, Unstable angina by
32%, and coronary
revascularization by 33%
3. ALLHAT-
LLT
Follow-up of
3.3 year
Pravastatin,
(20 and
40 mg)
10,355 All-cause
mortality; fatal
coronary heart
disease and
nonfatal MI
Fatal CHD and
nonfatal MI,
stroke, CHF,
cancer
There was no difference in
mortality, CHD or stroke
compared with usual care
for moderate
hypercholesterolemia
4. ASCOT-
LLA
Mean follow
up 4.8 years
Atorvastatin
(10 mg)
10,305 Nonfatal MI and
fatal CHD
Coronary events;
all cause
mortality; fatal/
nonfatal stroke
Primary endpoint was
significantly reduced (1.9%
versus 3.0%); insignificant
reduction in all cause
mortality but trended
towards reduction; total
cholesterol reduced by 24%
at 12 months and 19% after
3 years compared with
placebo
5. CARDS 4 years Atorvastatin
(10 mg/d or
placebo)
2838 First occurrence
of acute coronary
events, coronary
revascularization
or stroke
Total mortality,
any CV
endpoints, lipids
and lipoproteins
Reduction in major CV
events by 37%
6. ASPEN Follow up
2.4 years
Atorvastatin
10 mg
2410 First occurrence
of composite
clinical endpoints
of CV death, MI,
stroke,
recanalization,
worsening angina
Insignificant reduction in the
primary composite end
point comparing 10 mg of
atorvastatin with placebo
(13.7 and 15.0%)
7. MEGA Mean follow-
up 5.3 years
Pravastatin
(10–20 mg/d)
7832 First occurrence
of CHD
Reduction of CHD risk by
33% compared with
diet alone
8. JUPITER Median
follow up
1.9 years
(trail halted);
maximal
follow up
5 years
Rosuvastatin
(20 mg/d)
17,802 First major CV
(nonfatal MI,
nonfatal stroke,
hospitalization
for UA, arterial
revascularization
procedures and
confirmed CV
deaths
Components of
primary
endpoints
considered
individually
44% reduction in primary
end point of all vascular
events, 54% reduction in MI,
48% reduction in stroke, 46%
reduction in need for arterial
revascularization, and 20%
reduction in all cause
mortality. (trial halted on the
recommendation of
independent data and safety
monitoring board)
CHF = congestive heart failure; CHD = coronary heart disease; CV = cardiovascular; MI = myocardial ischemia; UA = unstable angina; N = No. of
patients. AFCAPS/TeXCAPS = Air Force/Texas Coronary Atherosclerosis Prevention Study Air Force/Texas Coronary Atherosclerosis Prevention
Study; ALLHAT–LLT = Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack–Lipid Lowering Trial; ASCOT–LLA = Anglo-
Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm; ASPEN = Atorvastatin for Prevention of Coronary Heart Disease Endpoints in
Non-insulin Dependent Diabetes Mellitus; CARDS = Collaborative Atorvastatin Diabetes Study; JUPITER = Justification for the Use of Statins in
Prevention: an Intervention Trial Evaluating Rosuvastatin; MEGA = Management of Elevated Cholesterol in Primary Prevention of Adult Japanese;
WOSCOPS = West of Scotland Coronary Prevention Study.
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tors to reduce the risk of ASCVD events.
Therefore, the new guidelines justified reducing
LDL-C level to at least half with high-intensity
statin therapy. However, high dose statin alone
cannot lower LDL-C adequately to reduce the risk
of ASCVD events in individuals with such a high
LDL-C level. Addition of non-statin cholesterol-
lowering medications may be required besides
prescribing a maximal tolerated statin dose to attain
desired LDL-C targets in such individuals [40].
Primary prevention in patients with diabetes
Strong evidence supports treatment of diabetic
patients aged 40–75 years with a moderate-inten-
sity statin dose. In diabetic patients, only one trial
of high-intensity statin therapy in primary pre-
vention was conducted but high level of evidence
was taken into consideration for cardiovascular
events with statin therapy reduction in individuals
with >7.5% estimated 10-year ASCVD risk and
who were non diabetic to recommend high-
intensity statin therapy than individuals with
diabetes and >7.5% estimated 10-year ASCVD
risk. Individuals with diabetes experience greater
morbidity and have worse rates of survival
following the onset of clinical ASCVD. Therefore,
personalization of statin therapy was recom-
mended in individuals with diabetes who are
<40 and >75 years of age considering ASCVD risk
reduction benefits, the potential for adverse
effects and drug-drug interactions, and patient
preferences [41,42].
Primary prevention in non-diabetic patients and
patients with LDL-C 70–189 mg/dL
Recent guidelines have recommended statin
therapy based on an estimated 10-year ASCVD
risk, regardless of sex, race or ethnicity, and in
individuals aged 40–75 years with LDL-C levels
between 70 and 189 mg/dL who were without clin-
ical ASCVD or diabetes. Point estimates of statin-
associated reductions in the relative risk of
ASCVD in primary prevention reveal a similar
reduction of ASCVD risk in both men and women.
There was also no evidence that the ASCVD risk-
reduction benefit or adverse-effect profiles dif-
fered by race. Statin therapy was recommended
to individuals with P7.5% estimated 10-year risk
for ASCVD and LDL-C 70 to189 mg/dL in spite
of the fact that these individuals aged 40–75 years
were not prior candidates for statin therapy based
on the presence of clinical ASCVD, diabetes, or
LDL-C P190 mg/dL. It was reported that only
one exclusively primary prevention randomizedclinical trial had included individuals with
LDL-C 70 to <100 mg/dL. However, the Choles-
terol Treatment Trialists Collaboration 2010 meta-
analysis found a relative reduction in ASCVD
events of similar magnitude across the spectrum
of LDL-C levels >70 mg/dL [41,42].Primary prevention with statins in CVD in
past and present treatment guidelines
In some way or another, several guidelines have
advocated the use of statins. However, there
remains a lack of consensus among the global
medical community on the primary prevention
of CVD with statins.
The National Cholesterol Education Program
Adult Treatment Panel (NCEP-ATP) III guidelines
recommend the primary prevention with statins
for LDL-C level P190 mg/dL (5.0 mmol/L) and
advise on the use of clinical judgment for LDL-C
between 160 and 189 mg/dL (4.1–4.9 mmol/L).
They do not recommend statin use in apparently
healthy subjects with an LDL-C <160 mg/dL
(4.1 mmol/L), unless an individual presents with
two or more CVD risk factors [16]. Statins were
recommended as the drug of choice for lowering
high blood cholesterol in European guidelines
such as the European Society on Cardiology
(ESC)/European Atherosclerosis Society (EAS)
guidelines for the management of dyslipidemia,
as well as in the revised version of the ESC/EAS
guidelines on CVD prevention. The ESC/EAS
guidelines arbitrarily divided asymptomatic
population into two groups based on particular
LDL-C cutoffs. The first group included individu-
als at high risk based on Systematic Coronary Risk
Estimation (SCORE) > 5%, and in whom preven-
tive action should be maximized. This was misin-
terpreted by many physicians (sympathizers of
the pharmaceutical manufacturers) that everyone
in this group should take lipid-lowering drugs.
The second group included those with
SCORE < 5%. Individuals in this group were not
recommended preventive action nor prescribed
drugs. In 2012, a revised version of the European
guidelines on CVD prevention was published.
The revised guidelines deemed wrong the pre-
scription of statin to individuals falling in the
above two categories, which are quite prevalent
in clinical practices [43,44]. The revised ESC/EAS
guidelines also had the demerit in that they
recommended statin use based on CVD-risk
estimation as per SCORE charts, and did not
use any target LDL-C levels. Total CVD-risk is
known to be intricately linked to a multitude of
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ESC/EAS guidelines, cutoffs defining ‘high-risk
group’ are random and based on risk-levels at
which patients show benefit in clinical studies
[45,46]. Therefore, ESC/EAS guidelines advocate
the adoption of an individualized approach to sta-
tin prescription [45].
The recent American College of Cardiology
(ACC)/American Heart Association (AHA) guide-
lines, released in November 2013, recommended a
more aggressive use of statin, and emphasized the
need to prevent stroke and CVDs by focusing on
statin therapy instead of achieving LDL-C targets
using pharmacotherapeutic agents [42]. Accord-
ingly, as per the new ACC/AHA guidelines, an
exhaustive statin therapy is superior to a less
exhaustive statin therapy for patients. The new
ACC/AHA guidelines showed that individuals
with prior vascular disease or LDL-C = 4.9 mmol/L
[190 mg/dL] should be considered for high-
intensity statin therapy to achieve at least 50%
lowering of LDL-C. The advantages of statin use
on heart attack, stroke, and cardiovascular mortal-
ity considerably outweighed the risk of myopathy
or diabetes. These guidelines used a recently
developed risk prediction matrix based on ‘‘hard’’
atherosclerotic events to suggest statin therapy for
primary prevention of patients with a predicted
10-year riskP7.5%, and considered statin therapy
in individuals with 10-year risks of between 5%
and 7%. In type 1 or type 2 diabetic patients, the
threshold of P7.5% was used to make decisions
on using high-intensity or moderate-intensity reg-
imen with statins, and was defined as a daily reg-
imen of statin that lowered LDL-C by >50% or
between 30% and 50%, respectively. According
to the criteria of the recent AHA/ACC, over 45
million middle-aged Americans without CVD are
eligible for treatment with statins, and with the
new risk calculator, almost all men in the age
bracket of >66 years and women >70 have a 10-
year risk greater than 7.5% possessing favorable
risk factors that would require treatment with stat-
ins. Therefore, age alone could be used to screen
individuals for possible treatment with statin ther-
apy. With this approach, the new ACC/AHA
guidelines propose to simplify and improve care
for individuals with higher CVD risks, including
those with diabetes [42]. However, the potential
flaw in the recent ACC/AHA guidelines are that
they rely on the new risk prediction algorithm
which could justify primary prevention with statin
in many for whom trial evidence is lacking.
Further, it could put many out of the ambit of sta-
tin use despite clinical trial evidence suggestinguse of statin. Therefore, the recent ACC/AHA
guidelines urge clinicians to adopt an alternative
and simpler policy of assessing ‘‘what works best’’
and ‘‘in whom’’ than in predicting risk and pre-
suming benefits in primary prevention with statin
based on the available clinical trial data. This
would minimize undue statin prescription and
would help make evidence-based clinical recom-
mendations for statin therapy backed by clinical
data [22]. The recent ACC/AHA guidelines justify
the cost of generic statin medication as there is an
overall reduction in cardiovascular morbidity fol-
lowing primary prevention with statin therapy.
Primary prevention with statin resulted in a 29%
decrease in hospitalization rates and an average
reduction of 27% in overall healthcare costs
indicating cost effectiveness of statin therapy in
primary prevention [25].Discussion
In Saudi Arabia, coronary heart disease has been
one of the main health hazards and the third most
common cause of hospitalization and mortality,
followed by accident and senility. A surge in
CVD-related morbidity and mortality is natural
because of the large epidemiologic and nutritional
transition in the kingdom. Saudi Arabia has also
witnessed considerable economic growth, stan-
dard of living and life-style transformations,
including adoption of sedentary lifestyle and
access to higher energy diet intake, and increased
urbanization. These transitions have led to the
emergence of the epidemic of noncommunicable
diseases, and hence an increase in the number of
CVD-related deaths and disabilities. It was
reported that nations witnessing transitions from
conventional semi-urbanized lifestyles to western
lifestyles at a fast pace were susceptible to an
increase in populations with obesity and other car-
diovascular problems [47]. In 2004, Al-Nozha et al.
reported that the overall prevalence of coronary
artery diseases in Saudi Arabia was 5.5%, a figure
that was midway between those reported from
other countries [48]. High dietary fat intake, hyper-
tension, diabetes mellitus, smoking, and lack of
physical exercise have been commonly observed
risk factors among Saudi citizens with heart
diseases [49]. It is strange that by the time heart
problems are detected, the underlying cause (ath-
erosclerosis) has progressed to an advanced stage
[50]. Twenty years ago, a study from the Eastern
Province of Saudi Arabia reported that more than
26% of total deaths were from CVD alone [51].
The prevalence study reported that as the
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ity and mortality also rose several times. The pop-
ulation of Saudis aged 60 or more has grown
several folds over the last 20 years, and these
elderly people are vulnerable to various types of
heart diseases. In 2004, Al-Shehri et al. [52]
reported the presence of high-risk levels of total
cholesterol, LDL-C and triglycerides in 32.7%,
33.1%, and 34.1%, respectively, among school chil-
dren aged 9–12 years. In 2008, Al-Nozha et al. [53]
conducted a study over a five-year period between
1995 and 2000 with selected Saudis in the age
group of 30–70 years, and showed that the preva-
lence of hypercholesterolemia among males was
54.9% and 53.2% for females, and 53.4% among
urban Saudis and 55.3% among rural Saudis.
Males were reported to have a statistically signifi-
cant higher prevalence of hypertriglyceridemia
over 47.6% compared to 33.7% in females [53].
In a study of students, conducted at the King
Faisal University, Dammam, Saudi Arabia, the
presence of CVD risk factors was high, and a
quarter of the students reported not practicing
physical exercise at all, while 18.9% of them were
smokers. The study also reported that a high pro-
portion of university students consumed fast
foods, saturated fats, and soft drinks. Overweight
and obesity as measured by body mass index
(kilograms/square of the height in meters) and
unacceptable waist-to-hip ratios were evident in
Saudi students [49]. Obesity as measured by
waist-to-hip ratio is described as a better tool in
the prediction of CVD and mortalities related to
other heart diseases [54]. Several local studies
have also reported an increased prevalence of dia-
betes mellitus, smoking, obesity and hypercholes-
terolemia. In a 2012 study of 4490 Saudis aged
15 years and older Al-Kaabba et al. [55] reported
high prevalence of dyslipidemia in Saudi Arabia.
In 2013, Basulaiman et al. [56] conducted an epide-
miological study involving face-to-face interviews,
with a national multistage representative sample
of Saudis aged 15 years or older (10,735 partici-
pants) between April and June 2013. The study
reported that, overall, 8.5% of Saudis were
hypercholesterolemic, and another 19.6% were
borderline hypercholesterolemic. Of the hyper-
cholesterolemic Saudis, 65.1% were undiagnosed,
2.3% were treated uncontrolled, 28.3% were trea-
ted controlled, and 4.3% were untreated. The risk
of being hypercholesterolemic increased with age
and among individuals who reported consuming
margarine, obese individuals, and those who had
been previously diagnosed with hypertension or
diabetes [56]. The study concluded that more thana million Saudis were hypercholesterolemic and
0.7 million of them were unaware of their
condition, which could be controlled through
early detection. In a recent cross section study,
involving medical students of King Abdulaziz
University, an alarmingly high prevalence of
CVD risk factors were reported among medical
students, especially among males [57]. The risk
of mortality for patients with heart diseases is
well-known and a number of guidelines exist to
reduce this risk; yet, hypercholesterolemia among
patients in the six Arabian Gulf countries includ-
ing Saudi Arabia is still undertreated.
In light of such studies reporting higher preva-
lence rates of hypercholesterolemia and CVD-risk
factors in Saudi Arabia, there is an urgent call for
the aggressive management of dyslipidemia and
associated risk factors. Several guidelines are cur-
rently available for the management of dyslipide-
mia and CVD-risk factors, which now include the
new ACC/AHA guidelines. However, implemen-
tation of appropriate lipid management guidelines
would be an important step forward in containing
rising incidences of CVDs in the Kingdom of Saudi
Arabia. In a recent review, published in 2014, Ray
and colleagues conduct a comparison of the widely
used 2011 ESC/EAS guidelines and the new 2013
ACC/AHA guidelines [58]. Both the 2011 ESC/
EAS and the 2013 ACC/AHA guidelines have used
overall cardiovascular risk to assess any imminent
CVD risk and to make clinical decisions on
whether or not to prescribe lipid-modifying agent.
However, the new ACC/AHA guidelines focus pri-
marily on statins only because these are the most
widely prescribed lipid-modifying drugs to date
and whose benefits in the prevention of CVD have
been unambiguously established. Hence, reports
suggest that the new 2013 ACC/AHA guidelines
have a limited scope as they only consider
evidence from RCTs and ignore broad scientific
evidence [58]. The 2011 ESC/EAS guidelines have
a considerably greater scope as these consider all
the available evidence and not just clinical evi-
dence from randomized trials. Besides, 2011 ESC/
EAS guidelines stressed on the importance of all
lipids and provides practical guidance across a
wide range of conditions including ASCVD pre-
vention and dyslipidemia. The 2013 ACC/AHA
guidelines recommended high-intensity (high
dose) and moderate-intensity (moderate dose)
statins without regard to the risk of new-onset dia-
betes, myopathy and hemorrhagic shocks [42].
They recommended the statin doses that were
used in trials, and pushed for the achievement of
a 50% reduction in LDL-C using high-intensity
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20 mg), and a 30–50% reduction using moderate
intensity statins (atorvastatin 10 mg, simvastatin
20 or 40 mg, pravastatin 40 mg, fluvastatin 40 mg,
twice daily, and rosuvastatin 10 mg). However, it
is worthy to note here that rosuvastatin 40 mg as
high-intensity statin, and atorvastatin 20 mg and
rosuvastatin 5 mg doses are not RCT tested but
are doses approved by the Food and Drug
Administration, USA. There is no hard RCT evi-
dence suggesting 50% reduction of LDL-C and
therefore it would be incorrect to make it the only
criteria in the recommendation of statins. The new
ACC/AHA guidelines are in complete contradic-
tion with the existing NCEP-ATP III and other
international guidelines, all of which all have spec-
ify LDL-C goals. Further, the 2013 ACC/AHA
guidelines were unable to explain the role of addi-
tional lipid-lowering therapies in individuals who,
regardless of achieving 50% reduction in LDL-C,
show high residual absolute-risk. The 2011 ESC/
EAS guidelines have recommended specific LDL-C
targets for each level of absolute risk as they
categorize people into moderate and very high
CVD risks. Moreover, the 2011 ESC/EAS guide-
lines recommend LDL-C and other lipid measures
to monitor efficacy, compliance, and residual risk,
and leave considerable scope to individualized
patient-care and consideration of additional thera-
pies as per the clinical situation [44,45]. The further
reported weakness in the 2013 ACC/AHA
guidelines was that they offered guidance only
on treating those at risk of ASCVD and did not
consider lipid fractions as potential markers of
CVD, other than LDL-C [42]. On the other hand,
the 2011 ESC/EAS guidelines provided a system-
atic approach in the treatment of CVD risk and
broader understanding of LDL-C in CVD risk
assessment. They also placed emphasis on the
monitoring of LDL-C for measuring therapeutic
efficacy and patient compliance. The advantage
of the 2011 ESC/EAS guidelines was that they pro-
vided a realistic clinical solution for the utility of
other lipid fractions that the new ACC/AHA
guidelines ignored, such as triglycerides-rich lipo-
proteins, remnants, and conditions associated with
low HDL-C, non-HDL-C or apolipoprotein B.
These lipid fractions are reported as informative
and can help in clinical decision-making. In
addition to the traditional-risk factors, ESC/EAS
guidelines also recognized other factors which
included elevated social deprivation, central
obesity, triglycerides, elevated lipoprotein (a),
subclinical atherosclerosis, or family history of
premature CVD which may further influenceabsolute risk. In contrast, very high HDL-C or
family history of longevity was also part of the
consultation with the patient before prescribing
lipid-modifying therapy. Both guidelines, how-
ever, were unanimous in their suggestions for
lifestyle modifications and emphases on making
patients partners in disease prevention, and both
underscored the importance of clinical judgment
over guidelines in individual cases.
In primary prevention, the new ACC/AHA
guidelines recommend that statin treatment
should be initiated in individuals with a 10-year
ASCVD risk of P7.5% compared to previous rec-
ommendations prescribing a considerably higher
threshold for 10-year risk of fatal and non-fatal
coronary heart disease. In the SCORE model, the
ACC/AHA 10-year threshold of 7.5% is equivalent
to a 2.5% risk for CVD death over 10 years, and
individuals with a 10-year risk of fatal CVD of
2.5% are regarded as at moderate risk. In that sit-
uation, the ESC/EAS recommends the LDL-C goal
of 3 mmol/L. The 2013 ACC/AHA-prescribed
threshold for primary prevention, if applied,
would complicate healthcare by increasing multi-
fold the number of people receiving statins over
the number of people who should receive statin
doses, and who in many cases may end up receiv-
ing higher doses than prescribed. In turn, this
would considerably raise healthcare costs.
Similarly, as more people receive moderate to
high-intensity statin doses, there would be a man-
ifold increase in statin side-effects complaints
and/or the development of statin intolerance.
Therefore, the practicality of extending statin use
to an even wider group is worthy of reconsidera-
tion, even if the benefits with statins across a
range of clinical conditions is unequivocally estab-
lished. Almost all the world guidelines, including
Asia, Australia, and Canada, have given due con-
sideration to evidence beyond RCTs and prescribe
lipid goals to monitor the response to lipid modi-
fication therapy and compliance of patient. Hence,
lipid management guidelines from the rest of the
world resemble the 2011 ESC/EAS guideline and
not the new ACC/AHA guidelines. The guidelines
used in most parts of the world are designed to
provide a holistic lipid-management solution that
could be applied to a large patient-population.
Furthermore, the ACC/AHA mixed pooled
cohorts equation cannot be applied globally as
patients from other countries, such as south-east
Asia, the Indian subcontinent, Pacific islanders
including Maori and Australian aboriginals, were
not included in the clinical trials. In some ethnic
groups, a higher number of statin side-effects
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2013 ACC/AHA guidelines are impractical in the
Asia–Pacific region [58]. The comparison of the
new ACC/AHA guidelines vis-à-vis the 2011
ESC/EAS guidelines indicate that it would not be
appropriate to draw primary prevention guidance
from the new ACC/AHA guidelines which is
riddled with fallacies. The pattern of CVD-risk
factors prevalent in Saudi Arabia are mostly
observed as lifestyle-related which include smok-
ing, lack of exercise, and low fibrous diets.
Implementing the new ACC/AHA guidelines
would lead to the inclusion of a large population
for statin therapy, to an increase in the number
of people with statin intolerance and an increase
in myopathy, diabetes mellitus, hepatic impair-
ment, rash and flushing, and neurological disor-
ders. It would be more practical to adopt and
seek guidance from the 2011 EAS/ESC guidelines,
which provide a comprehensive approach to
dyslipidaemia management for primary preven-
tion with statins in the Kingdom of Saudi Arabia.Conclusion
There is a prevalence of lipid-related disorders
in Saudi Arabia which mostly results from lifestyle
changes. It is preferable to prescribe statin
primary prevention to a select few in order to
avoid overmedicating the general population.
Since the release of the new ACC/AHA guide-
lines, there has been an ever increasing world-
wide prevalence of CVD and a confusion has
prevailed in many regions which do not have their
own guidelines. The reduction of primary preven-
tion threshold, as prescribed by the new ACC/
AHA guidelines may benefit younger patients
with high absolute lifetime risk, but may lead to
over-treatment of older patients, due to the over-
emphasis on age. The new ACC/AHA guidelines
are riddled with fallacies and a comparison
vis-à-vis ESC/EAS guidelines emphasize that its
general adoption could result in the unnecessary
prescription of statins to a large number of
patients, potentially at considerable cost.
Therefore, considering the prevailing clinical data
on CVD in Saudi Arabia, the 2011 ESC/EAS guide-
lines for lipid modification appear to be the most
wide-ranging, realistic, and appropriate option.
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